Many pieces of research have demonstrated that ITP patients have decreased Tregs, and interestingly, several medications that boost platelet cell number in ITP, such as glucocorticoid, rituximab, and intravenous immunoglobulin (IVIG), appear to do so via normalization of Tregs (Zufferey et al., 2017), (Semple et al., 2010), Thus these findings suggesting that silencing of IFNG-AS1 is a potential target of therapy for ITP. The gene discussed is IFNG; the disease is autoimmune thrombocytopenic purpura.